Contents:

Chapter 1: Executive Summary Chapter 2: Introduction To Angiogenesis Overview of Angiogenesis The Process of Angiogenesis Molecules Involved in Angiogenesis Growth Factors and Other Angiogenic Proteins Receptor Tyrosine Kinases Proteases Cell Adhesion Molecules Endogenous Antiangiogenic Proteins Role of Angiogenesis in Disease Approaches to Angiogenesis Modulation Types of Drugs under Development Small-Molecule Drugs Biopharmaceuticals Assays for Angiogenesis Chapter 3: Angiogenesis In Cancer Overview of Cancer Cancer Therapy Molecular Targeted Therapies Angiogenesis in Cancer Angiostatic versus Angiolytic Therapies Targets for Angiostatic Therapies Growth Factors and Their Receptors VEGF-A VEGFR Family EGFR Family Small-Molecule Drugs Monoclonal Antibody Drugs Other Growth Factors/Receptors Tie2 Receptor IGF1R FGF-2 VEGF-C, VEGF-D/VEGFR-3 PDGF(R) Multi-Target Strategies Applications in Hematologic Malignancies ECM-Degrading Enzymes Matrix Metalloproteases Heparanase Proteases (other than MMPs) ADAMs Family uPA Other Proteases Cell Adhesion Receptors Alpha(v) Integrins Other Cell Adhesion Receptors Agents Based on Human Antiangiogenic Factors Endogenous Antiangiogenic Factors Antiangiogenic Gene Therapy Agents of Non-Human Origin Miscellaneous Agents Thalidomide-Related Drugs Other Drugs Angiolytic Vascular Targeting Agents Small-Molecule VTAs Tubulin-Binding Agents Other Small-Molecule Agents Ligand-based and Other VTAs Exploiting Angiogenesis for Drug Delivery Chapter 4: Angiogenesis In Cardiology Overview of Cardiovascular Disease Coronary Artery Disease Established Treatments Myocardial Infarction Current Treatments Peripheral Vascular Disease Current treatments Congestive Heart Failure Current Treatments Angiogenesis in Ischemia Physiological Responses to Ischemia Stimulation of Angiogenesis in Ischemia Transmyocardial Revascularization Therapeutic Angiogenesis Cell Therapy Challenge of Pathologic Angiogenesis Atherogenesis and Atheroscleropathy Percutaneous Coronary Interventions Approaches to Restenosis Prevention Angiogenesis Modulators Angiogenic Products in Commercial Development Protein and Small Molecule Therapies Gene Therapies Cell Therapies Stem and Progenitor Cell Therapies Chapter 5: Angiogenesis In Ophthalmology Eye Diseases Involving Neovascularization Age-related Macular Degeneration Diabetic Retinopathy Other Disorders Angiolytic Photodynamic Therapy Angiogenesis-targeting Drugs Angiostatic Drugs Targeting VEGF/VEGFR Miscellaneous Targets Vascular Targeting Agents Chapter 6: Other Applications Of Angiogenic Modulation Introduction Skin Diseases Chronic Wounds Vascular Lesions Psoriasis Rosacea Other Vascular Lesions Chronic Inflammatory Diseases Rheumatoid Arthritis Periodontitis Inflammatory Bowel Disease Inflammatory Lung Diseases Complex Regional Pain Syndrome Fibrodysplasia Ossificans Progressiva Transplant Rejection Orthodontic Applications Spinal Cord Injuries Other Potential Applications Endometriosis Obesity Erectile Dysfunction Benign Tumors Chapter 7: Company Profiles Introduction Abbott Laboratories AEterna Zentaris Inc Alcon Laboratories Inc Amgen Inc Angiotech Pharmaceuticals Inc Antisoma Plc AstraZeneca Plc Bayer AG Boston Scientific Corporation Celgene Corporation Collagenex Pharmaceuticals Inc Collateral Therapeutics Inc Corautus Genetics Inc EntreMed Inc EyeTech Pharmaceuticals Inc Genaera Corporation Genentech Inc Genzyme Corporation GlaxoSmithKline Plc Human Genome Sciences ImClone Systems Inc Merck KGaA Merck & Co Inc Novartis Pharma AG OSI Pharmaceuticals Inc OXiGENE Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Sirna Therapeutics Inc Valentis Inc Chapter 8: The Angiogenesis Modulation Market To 2009 Introduction Cancer Overview Established Cancer Therapies The Anti-Cancer Drug Market Cardiology Overview Coronary Artery Disease Myocardial Infarction Congestive Heart Failure Established Treatments Cardiology drug market Ophthalmology Overview Age-related Macular Degeneration Diabetic Retinopathy Other Eye Disorders Ophthalmology Drug Market Dermatology Overview Psoriasis Benign Vascular Lesions Impaired Wound Healing Dermatology Drug Market Other Indications Market Forecasts Chapter 9: Conclusions, Trends, and Opportunities Gap Narrows between Experimental and Clinical Data VEGF Inhibitors Lead the Way Cancer: Opportunities Expand Accelerating Approvals Learning from Clinical Trials Optimizing Therapies Towards Pharmacogenomic Testing Towards Angiogenic Profiling Taking Advantage of Vascular Targeting Future Horizons—Cancer Prevention? AMD: Breakthrough Treatments Emerge Cardiology: Interest Peaks Despite Slow Progress Other Diseases: Largely Unexplored Opportunities Exploiting Unexpected Angiomodulatory Effects TABLE OF EXHIBITS Exhibit 2.1 Partial List of Endogenous Angiogenic Factors Exhibit 2.2 Partial List of Endogenous Antiangiogenic Factors Exhibit 3.1 Cancer: Inhibitors of Growth Factors/receptors Listed by Drug Target Exhibit 3.2 Cancer: Inhibitors of ECM-degrading Enzymes, List by Drug Target Exhibit 3.3 Cancer: Inhibitors of Proteases (other than MMPs), Listed by Drug Target Exhibit 3.4 Cancer: Inhibitors of Cell Adhesion Receptors Exhibit 3.5 Cancer: Agents Based on Human Antiangiogenic Factors Exhibit 3.6 Cancer: Antiangiogenic Substances of Non-human Origin Exhibit 3.7 Cancer: Miscellaneous Agents with Antiangiogenic Properties Exhibit 3.8 Cancer: Vascular Targeting Agents Exhibit 4.1 Cardiovascular Diseases: Angiogenic Therapies Exhibit 5.1 Vascular Eye Diseases: Antiangiogenic Therapies Exhibit 6.1 Dermatology: Angiogenic and Antiangiogenic Therapies Exhibit 6.2 Miscellaneous Indications: Antiangiogenic Therapies Exhibit 7.1 The 25 Most Active Organizations in Angiogenesis-related US Patenting, 1995 - 2004 (Granted Patents) Exhibit 7.2 The 25 Most Active Organizations in Angiogenesis-related US Patenting, 2002 - 2004 (Published Applications) Exhibit 7.3 The 25 Most Frequently Cited Angiogenesis-related US Patents, 1995 - 2004 Exhibit 8.1 World Prevalence Of Angiogenesis-Related Diseases Exhibit 8.2 World Market For Angiogenesis-Related Diseases Exhibit 8.3 World Pharma Market In 2004 and 2009 Exhibit 8.4 Angiogenesis-Related Markets By Indication Exhibit 8.5 World Angiogenesis-Related Market In 2004 And 2009

Companies Mentioned

-Abbott Laboratories -AEterna Zentaris Inc -Alcon Laboratories Inc -Amgen Inc -Angiotech Pharmaceuticals Inc -Antisoma Plc -AstraZeneca Plc -Bayer AG -Boston Scientific Corporation -Celgene Corporation -Collagenex Pharmaceuticals Inc -Collateral Therapeutics Inc -Corautus Genetics Inc -EntreMed Inc -EyeTech Pharmaceuticals Inc -Genaera Corporation -Genentech Inc -Genzyme Corporation -GlaxoSmithKline Plc -Human Genome Sciences -ImClone Systems Inc -Merck KGaA -Merck & Co Inc -Novartis Pharma AG -OSI Pharmaceuticals Inc -OXiGENE Inc. -Pfizer Inc. -Regeneron Pharmaceuticals Inc. -Sirna Therapeutics Inc -Valentis Inc